LPAR2 and acquired polycythemia vera: Given that GRI treatment significantly reduces circulatory RBC numbers, our results suggest the potential application of LPA2 agonists on several myeloproliferative diseases, including thrombocythemia, polycythemia vera, and primary myelofibrosis41.